← Patent-cliff monitor small molecule TRUQAP CAPIVASERTIB
Loss of exclusivity April 2033 latest FDA-listed patent expiry
Company ASTRAZENECA PHARMACEUTICALS LP
Drug detail Brand name TRUQAP Active ingredient CAPIVASERTIB Strength 200MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval November 2023 Marketing status RX
Listed patents Patent Expires Type 10039766 April 2033 use U-4559 9487525 April 2033 substance, product 8101623 March 2030 substance, product 11236095 October 2028 use U-4559 9492453 October 2028 use U-4559 10059714 October 2028 substance, product 12252495 October 2028 use U-3762 10654855 October 2028 use U-3762 11760760 October 2028 use U-3762
Regulatory exclusivity Code Expires I-991 June 2029 NCE November 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.